Bg pattern

CARGLUMIC ACID TILLOMED 200 mg DISPERSIBLE TABLETS

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use CARGLUMIC ACID TILLOMED 200 mg DISPERSIBLE TABLETS

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Carglumic Acid Tillomed 200 mg Dispersible Tablets EFG

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Your medicine will be referred to as “carglumic acid” throughout this leaflet.

Contents of the pack

  1. What is Carglumic Acid Tillomed and what is it used for
  2. What you need to know before you take Carglumic Acid Tillomed
  3. How to take Carglumic Acid Tillomed
  4. Possible side effects
  5. Storing Carglumic Acid Tillomed
  6. Contents of the pack and other information

1. What is Carglumic Acid Tillomed and what is it used for

Carglumic acid can help eliminate excessive plasma levels of ammonia (high levels of ammonia in the blood). Ammonia is especially toxic to the brain and can cause, in severe cases, a decrease in the level of consciousness and coma.

Hyperammonemia can be due to

  • the lack of a specific liver enzyme (N-acetylglutamate synthase). Patients with this rare disorder are unable to eliminate nitrogen waste, which accumulates after ingesting proteins.
  • This disorder persists throughout the patient's life, so this treatment is necessary for life.
  • isovaleric acidemia, methylmalonic acidemia, or propionic acidemia. Patients who suffer from one of these disorders need treatment during the hyperammonemia crisis.
Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you take Carglumic Acid Tillomed

Do not take Carglumic Acid Tillomed:

  • if you are allergic to carglumic acid or any of the other ingredients of this medicine (listed in section 6).
  • while breastfeeding (see section Pregnancy and breastfeeding).

Warnings and precautions

Consult your doctor or pharmacist before taking carglumic acid.

Treatment with carglumic acid should be initiated under the supervision of a doctor with experience in the treatment of metabolic disorders.

Your doctor will assess your individual response to carglumic acid before starting any long-term treatment.

The dose should be adjusted individually to maintain normal plasma ammonia levels.

Your doctor may prescribe arginine supplements or limit your protein intake.

In order to monitor your disease and treatment, your doctor may periodically examine your liver, kidneys, heart, and blood.

Other medicines and Carglumic Acid Tillomed

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including those obtained without a prescription.

Using Carglumic Acid Tillomed with food and drinks

Carglumic acid should be taken orally before main meals or food intake. The tablets should be dispersed in a minimum of 5 to 10 ml of water and taken immediately. The suspension has a slightly acidic taste.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before taking this medicine.

Pregnancy

The effects of carglumic acid on pregnancy and the fetus are unknown.

Breastfeeding

It has not been studied whether carglumic acid passes into human breast milk. However, it has been shown that carglumic acid is present in the milk of lactating rats, with possible toxic effects on the suckling pups. Therefore, you should not breastfeed your child if you are taking Carglumic Acid Tillomed.

Driving and using machines

The effects on the ability to drive and use machines are unknown.

Carglumic Acid Tillomed contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially "sodium-free".

3. How to take Carglumic Acid Tillomed

Follow exactly the administration instructions of this medicine given by your doctor. If you are unsure, consult your doctor or pharmacist again.

The tablet can be divided into two equal halves.

The usual dose:

The initial daily dose is usually 100 mg per kilogram of body weight, up to a maximum of 250 mg per kilogram of body weight (for example, if you weigh 10 kg, you should take 1 g per day or 5 tablets).

For patients with N-acetylglutamate synthase deficiency, the long-term daily dose usually ranges from 10 mg to 100 mg per kilogram of body weight.

Your doctor will determine the suitable dose for you to maintain normal ammonia levels in your blood.

Carglumic acid should be administered ONLY orally or through a nasogastric tube (using a syringe if necessary).

When the patient is in hyperammonemic coma, carglumic acid is administered by rapid infusion with a syringe through the tube used for feeding.

Tell your doctor if you have kidney failure. Your daily dose should be reduced.

If you take more Carglumic Acid Tillomed than you should

If you accidentally take too many tablets, contact your doctor or the nearest hospital emergency department immediately for advice. Remember to bring this leaflet or the remaining tablets with you.

You can also consult your pharmacist or call the Toxicological Pharmacovigilance Service. Phone 91 562 04 20, indicating the medicine and the amount taken.

If you forget to take Carglumic Acid Tillomed

Take it as soon as you remember, unless it is almost time for your next dose. Do not take a double dose to make up for the forgotten dose.

If you stop taking Carglumic Acid Tillomed

Do not stop taking carglumic acid without first consulting your doctor.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Seek medical attention immediately if you develop the following symptoms:

  • Allergic reactions: Swelling of the face, throat, or tongue, difficulty breathing, dizziness.

Common (may affect up to 1 in 10 people):

  • increased sweating

Uncommon (may affect up to 1 in 100 people):

  • slower heartbeats (bradycardia)
  • diarrhea
  • fever
  • increased transaminases
  • feeling sick (vomiting)

Frequency not known (cannot be estimated from the available data)

  • skin rash

If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storing Carglumic Acid Tillomed

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the blister and carton after "EXP". The expiry date is the last day of the month stated.

This medicine does not require any special storage conditions.

Medicines should not be disposed of via wastewater or household waste. Dispose of the packaging and any unused medicine in the SIGRE collection point at your pharmacy. If you are unsure, ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.

6. Contents of the pack and other information

Composition of Carglumic Acid Tillomed

  • The active substance is carglumic acid. Each tablet contains 200 mg of carglumic acid.
  • The other ingredients are microcrystalline cellulose (E460), hypromellose (E464), sodium lauryl sulfate, croscarmellose sodium (E468), colloidal anhydrous silica (E551), and sodium stearyl fumarate (E485).

Appearance and packaging

Carglumic Acid Tillomed is available in smooth aluminum/PAP/PET lidding material and aluminum-aluminum blister packaging, with 5, 15, and 60 dispersible tablets per pack.

Not all pack sizes may be marketed.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder

Laboratorios Tillomed Spain, S.L.U.

c/ Cardenal Marcelo Spinola, 8

28016 Madrid (Spain)

Manufacturer

Tillomed Malta Limited,

Malta Life Sciences Park,

LS2.01.06 Industrial Estate,

San Gwann, SGN 3000, Malta

This medicine is authorized in the Member States of the European Economic Area under the following names:

Country Name

Product Name

Germany

Carglumsäure Zentiva 200 mg Tabletten zur Herstellung einer Suspension zum Einnehmen

Spain

Ácido Carglúmico Tillomed 200 mg comprimidos dispersables EFG

France

ACIDE CARGLUMIQUE TILLOMED 200 mg, comprimé dispersible sécable

Greece

Carglumic acid Tillomed 200mg διασπειρ?μενα δισκ?α

Netherlands

Carglumaatzuur Tillomed 200 mg dispergeerbare tabletten

Date of last revision of this leaflet:February 2025

Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/

Online doctors for CARGLUMIC ACID TILLOMED 200 mg DISPERSIBLE TABLETS

Discuss questions about CARGLUMIC ACID TILLOMED 200 mg DISPERSIBLE TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for CARGLUMIC ACID TILLOMED 200 mg DISPERSIBLE TABLETS?
CARGLUMIC ACID TILLOMED 200 mg DISPERSIBLE TABLETS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in CARGLUMIC ACID TILLOMED 200 mg DISPERSIBLE TABLETS?
The active ingredient in CARGLUMIC ACID TILLOMED 200 mg DISPERSIBLE TABLETS is carglumic acid. This information helps identify medicines with the same composition but different brand names.
Who manufactures CARGLUMIC ACID TILLOMED 200 mg DISPERSIBLE TABLETS?
CARGLUMIC ACID TILLOMED 200 mg DISPERSIBLE TABLETS is manufactured by Laboratorios Tillomed Spain S.L.U. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of CARGLUMIC ACID TILLOMED 200 mg DISPERSIBLE TABLETS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether CARGLUMIC ACID TILLOMED 200 mg DISPERSIBLE TABLETS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to CARGLUMIC ACID TILLOMED 200 mg DISPERSIBLE TABLETS?
Other medicines with the same active substance (carglumic acid) include CARGLUMIC ACID WAYMADE 200 mg DISPERSIBLE TABLETS, CARBAGLU 200 mg DISPERSIBLE TABLETS, CARBAGLU 200 mg DISPERSIBLE TABLETS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media